Lee YS, Jun HS. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism. 2014;63(1):9–19. https://doi.org/10.1016/j.metabol.2013.09.010.

Article  CAS  PubMed  Google Scholar 

Kosiborod MN, Abildstrom SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069–84. https://doi.org/10.1056/NEJMoa2306963.

Article  CAS  PubMed  Google Scholar 

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–32. https://doi.org/10.1056/NEJMoa2307563.

Article  CAS  PubMed  Google Scholar 

He L, Wang J, Ping F, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022;182(5):513. https://doi.org/10.1001/jamainternmed.2022.0338.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Silverii GA, Monami M, Gallo M, et al. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2024;26(3):891–900. https://doi.org/10.1111/dom.15382.

Article  CAS  PubMed  Google Scholar 

Dillinger K. FDA looking into reports of hair loss, suicidal thoughts in people using popular drugs for diabetes and weight loss. In: CNN. 2024. https://www.cnn.com/2024/01/03/health/glp1-agonist-side-effects-fda/index.html. Accessed 7 Feb 2024.

Reuters. E.U. investigates Ozempic, Saxenda after suicidal thoughts reported. In: NBC News. 2023. https://www.nbcnews.com/news/world/eu-investigates-ozempic-saxenda-suicidal-thoughts-reported-rcna93552. Accessed 7 Feb 2024.

Pelc C. Can GLP-1 drugs Ozempic and Wegovy cause suicidal ideation, hair loss? In: MedicalNewsToday. 2024. https://www.medicalnewstoday.com/articles/ozempic-wegovy-side-effects-suicidal-ideation-hair-loss. Accessed 7 Feb 2024.

Manalac T. FDA probes GLP-1 receptor agonists on reports of suicidal thoughts, hair loss. In: BioSpace. 2024. https://www.biospace.com/article/novo-lilly-weight-loss-drugs-under-fda-scrutiny-for-suicidal-thoughts-hair-loss/. Accessed 8 Feb 2024.

EMA statement on ongoing review of GLP-1 receptor agonists. In: European Medicines Agency. 2023. https://www.ema.europa.eu/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists. Accessed 8 Feb 2024.

Semaglutide Responsible Use | Official Website. In: novoMEDLINK. https://www.novomedlink.com/semaglutide.html. Accessed 8 Feb 2024.

Pozsgai K, Szűcs G, Kőnig-Péter A, et al. Analysis of pharmacovigilance databases for spontaneous reports of adverse drug reactions related to substandard and falsified medical products: a descriptive study. Front Pharmacol. 2022;13:964399. https://doi.org/10.3389/fphar.2022.964399.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Böhm R, Von Hehn L, Herdegen T et al. OpenVigil FDA – inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications. PLOS ONE. 2016;11(6):e0157753. https://doi.org/10.1371/journal.pone.0157753.

Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug. 2001;10(6):483–6. https://doi.org/10.1002/pds.677.

Article  CAS  Google Scholar 

Ramya. 46: The Information Component | Pharmacovigilance. In: All About Pharmacovigilance. 2020. https://allaboutpharmacovigilance.org/46-the-information-component/. Accessed 8 Feb 2024.

Obesity Medicines & Food Industry Impact. In: Morgan Stanley. 2023. https://www.morganstanley.com/ideas/obesity-drugs-food-industry. Accessed 8 Feb 2024.

Chen C, Zhou R, Fu F, Xiao J. Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis. Eur Psychiatr. 2023;66(1):e99. https://doi.org/10.1192/j.eurpsy.2023.2474.

Article  Google Scholar 

Wang W, Volkow ND, Berger NA, et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024;30(1):168–76. https://doi.org/10.1038/s41591-023-02672-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

O'Neil PM, Aroda VR, Astrup A et al. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab. 2017;19(11):1529–36. https://doi.org/10.1111/dom.12963.

Mui JV, Li L, Chou OHI, et al. Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong. Acta Diabetol. 2023;60(7):917–27. https://doi.org/10.1007/s00592-023-02063-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ruggiero R, Mascolo A, Spezzaferri A, et al. Glucagon-like peptide-1 receptor agonists and suicidal ideation: analysis of real-word data collected in the European pharmacovigilance database. Pharmaceuticals. 2024;17(2):147. https://doi.org/10.3390/ph17020147.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McIntyre RS, Mansur RB, Rosenblat JD, Kwan ATH. The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf. 2024;23(1):47–55. https://doi.org/10.1080/14740338.2023.2295397.

Article  CAS  PubMed  Google Scholar 

Andrade C. Metformin as a possible intervention for cardiometabolic risks in pediatric subjects exposed to antipsychotic drugs: (clinical and pricatical psychopharmacology). J Clin Psychiatry. 2016;77(10):1362–4. https://doi.org/10.4088/JCP.16f11196.

Article  PubMed  Google Scholar 

Guirguis A, Chiappini S, Papanti PG, et al. Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: insights from pharmacovigilance measures and unmasking analysis. Eur Neuropsychopharmacol. 2024;82:82–91. https://doi.org/10.1016/j.euroneuro.2024.02.003.

Article  CAS  PubMed  Google Scholar 

Milaneschi Y, Simmons WK, Van Rossum EFC, Penninx BW. Depression and obesity: evidence of shared biological mechanisms. Mol Psychiatry. 2019;24(1):18–33. https://doi.org/10.1038/s41380-018-0017-5.

Article  CAS  PubMed  Google Scholar 

Hansel B. GLP-1 agonists and suicide risk: is action needed? In: Medscape. 2023. https://www.medscape.com/viewarticle/996484. Accessed 9 Feb 2024.

Hung A, Maciejewski ML, Berkowitz TSZ, et al. Bariatric surgery and suicide risk in patients with obesity. Ann Surg. 2023;278(4):e760–5. https://doi.org/10.1097/SLA.0000000000005825.

Article  PubMed  Google Scholar 

Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus. JCM. 2022;12(1):145. https://doi.org/10.3390/jcm12010145.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guo EL, Katta R. Diet and hair loss: effects of nutrient deficiency and supplement use. Dermatol Pract Concept. 2017; 1–10. https://doi.org/10.5826/dpc.0701a01

Blackburn GL, Bistrian BR, Hoag C. Hair loss with rapid weight loss. Arch Dermatol. 1977;113(2):234.

Article  CAS  PubMed  Google Scholar 

Kobren SD. Misuse of ozempic for rapid weight loss can cause significant and perhaps permanent hair loss. In: Dermatology Times. 2023. https://www.dermatologytimes.com/view/misuse-of-ozempic-for-rapid-weight-loss-can-cause-significant-and-perhaps-permanent-hair-loss. Accessed 8 Feb 2024

Telogen effluvium: symptoms, causes, treatment & regrowth. In: Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/24486-telogen-effluvium. Accessed 9 Feb 2024.

Wegovy® STEP 4 Clinical Trial Results | Wegovy® (semaglutide) injection 2.4 mg. In: novoMEDLINK. https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/clinical-trial-4-results.html. Accessed 8 Feb 2024.

Shaefer CF, Kushner P, Aguilar R. User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad Med. 2015;127(8):818–26. https://doi.org/10.1080/00325481.2015.1090295.

Article  PubMed  Google Scholar 

Daniella Nunez KL. Glucagon-like peptide 1 receptor agonists and aspiration risk. In: OpenAnesthesia. 2023. https://www.openanesthesia.org/keywords/glucagon-like-peptide-1-receptor-agonists-and-aspiration-risk/. Accessed 8 Feb 2024.

Hashash JG, Thompson CC, Wang AY. AGA rapid clinical practice update on the management of patients taking GLP-1 receptor agonists prior to endoscopy: communication. Clin Gastroenterol Hepatol. 2023; S1542356523008698. https://doi.org/10.1016/j.cgh.2023.11.002.

Joshi GP. American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients (Adults and Children) on Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. In: American Society of Anesthesiologists. 2023. https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative. Accessed 8 Feb 2024.

Van Zuylen ML, Siegelaar SE, Plummer MP et al. Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists: concerns for delayed gastric emptying and pulmonary aspiration. Br J Anaesth. 2024; S0007091224000023. https://doi.org/10.1016/j.bja.2024.01.001.

Brunton S. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int J Clin Pract. 2014; 68(5):557–67. https://doi.org/10.1111/ijcp.12361.

Desai M. Pharmacovigilance and spontaneous adverse drug reaction reporting: challenges and opportunities. Perspect Clin Res. 2022;13(4):177. https://doi.org/10.4103/picr.picr_169_22.

Article  PubMed  PubMed Central  Google Scholar